Navigation Links
Breast Cancer Message Barred in Eli Lilly's Hometown
Date:11/3/2010

SAN FRANCISCO, Nov. 3, 2010 /PRNewswire-USNewswire/ --Breast Cancer Action (BCA) learned today that its efforts to deliver a message to Eli Lilly & Company via a billboard in Indianapolis have been blocked.  The message:  "Eli Lilly is making us sick.  Tell them to stop" was rejected by every billboard company in Indianapolis, Lilly's hometown.

Despite working within the guidelines of each billboard company contacted, the advocacy group has been turned down because of the content of the message.  At a time when political advertizing across the nation has reached an all time high, the rejection of BCA's message raises critical questions about who controls the media when it comes to public health.

"We are talking about women's health here.  A breast cancer organization's message about the impact of a drug company's behavior is being kept off billboards in the company's home town.  When corporate influence runs this deep, the public should be outraged. We certainly are," said BCA executive director Barbara Brenner.

The public's health is at stake.  Eli Lilly is the sole worldwide manufacturer of rBGH (recombinant bovine growth hormone also known as rBST) which is sold under the name Posilac and has long been linked to cancer.  The artificial hormone is given to dairy cows to stimulate milk production.

Breast Cancer Action's "Milking Cancer" campaign demands Eli Lilly stop manufacturing the artificial stimulant rBGH.  In September 2010, signatures were gathered from over 6,732 individuals—one for each day that rBGH has been on the market—committed to delivering a message to Eli Lilly via a billboard in Indianapolis. For more information see www.milkingcancer.org.

Breast Cancer Action is a non-profit education and advocacy organization that does not accept funding from pharmaceutical companies or any other organizatio
'/>"/>

SOURCE Breast Cancer Action
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CyberKnife Radiosurgery for Early-Stage Breast Cancer
2. 10 Tips for Breast Cancer Survivors
3. Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
4. 10 Tips for Breast Cancer Screening and Early Detection
5. Jefferson Radiology Becomes First Diagnostic Imaging Group in Connecticut to Add Automated Ultrasound Capability for Screening Women with Dense Breast Tissue
6. Alma Lasers Joins the Fight Against Breast Cancer with the Launch of the NEW SopranoXLi
7. SightLine Health Adds Naviscan PEM Technology to Breast Cancer Treatment Services
8. FUJIFILM Revitalizes Images of Health Breast Cancer Awareness Initiative
9. FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
10. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
11. Swiss Breast Cancer Patient Becomes First in World to Receive Treatment Using Gated RapidArc from Varian Medical Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- According to market research report, ... & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, ... Geography - Global Trends & Forecast to 2019", ... market on the basis of various types, applications, ... market size of each of these segments in ...
(Date:9/19/2014)... , Sept. 19, 2014  Lpath, Inc. ... in bioactive lipid-targeted therapeutics, announced today that it ... registered shares of common stock and 3,605,042 unregistered ... purchase price for one registered share of common ... unregistered share of common stock will be $3.475.  ...
(Date:9/19/2014)... September 19, 2014 Aufgrund ... den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch ... PDF, verfügbar unter pharmaserialisation.com , zeigt die ... jeweils in Kraft treten. Für international ... länger um das "ob", sondern darum, "wann" sie ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
(Date:9/19/2014)... brain structure could help predict how willing you are to ... Yale University found those with greater volume in a part ... more likely to engage in risky behavior than people with ... by the U.S. National Institute on Aging, involved two groups ... The researchers sought to determine how brain structure influences risk ...
(Date:9/19/2014)... News) -- Although there is mounting evidence that ... and older adults in the United States don,t ... new research. Less than one-quarter of adults ... the Department of Health and Human Services, the ... promoting health and fitness and staying independent, researchers ...
(Date:9/19/2014)... Alan Mozes HealthDay Reporter ... Cancer patients burdened by stress and family conflicts before ... their operation, a new study suggests. Investigators found ... have a nearly three times greater risk for complications ... of life. "We,ve long known that patient quality ...
(Date:9/19/2014)... 2014 Lipitor lawsuits ( http://www.thelipitorlawsuit.com/ ... to develop Type 2 diabetes continue to move forward ... District Court, District of South Carolina, Bernstein Liebhard LLP ... 12, 2014, discovery is underway and moving forward in ... Pfizer, Inc., the manufacturer of Lipitor, has produced millions ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3
... ATLANTA, Feb. 3 Brent McKenzie, based ... Consulting, the nation,s fastest growing,pharmacy benefit firm, ... Mr. McKenzie offers his clients over ... Benefits and Pharmacy Benefit Management arena.,Brent has ...
... Cancer Care Access, Efficiency and Quality; Created Based ... 3 /PRNewswire-USNewswire/ -- The National Policy ... the nation,s largest cancer treatment and research networks ... Principles for Reforming Cancer Care, designed to guide ...
... of medical research, study finds , , TUESDAY, Feb. 3 ... white parents to distrust medical research, which may explain ... So conclude University of Pittsburgh researchers who surveyed 190 ... to a primary-care clinic. , The parents were asked ...
... 2009) Green tea products have become regarded as a ... its benefit against a variety of diseases, including cancer. ... tea may counteract the anticancer effects of one cancer ... contraindicated for patients taking this medicine to ensure its ...
... study suggests that Capn4, a protein involved in cell ... after liver transplantation. Capn4 could potentially be used as ... These findings are in the February issue of ... Sons on behalf of the American Association for the ...
... popular assumptions about the health benefits of green tea, ... found that the widely used supplement renders a cancer ... lymphoma completely ineffective in treating cancer. , The ... extract (GTE) called EGCG destroys any anticancer activity of ...
Cached Medicine News:Health News:Brent McKenzie Joins ARMSRx Pharmacy Benefit Consulting 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 3Health News:Parental Distrust May Explain Lack of Black Children in Clinical Trials 2Health News:Green tea may negate the effects of a common cancer therapy 2Health News:Green tea may negate the effects of a common cancer therapy 3Health News:Protein predicts liver cancer recurrence and after transplantation 2Health News:USC study finds that green tea blocks benefits of cancer drug 2
...
A modular concept consisting of two J-Arms, to be fixed at any position of the skull clamp, allowing to the surgeon an unobstructed access to the surgical field....
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: